Cic edizioni internazionali
Il Giornale di Chirurgia

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance

Review, 225 - 235
doi: 10.11138/gchir/2016.37.5.225
Tag this article
Abstract
Enhanced HTML Full text PDF
Conventional therapeutic approaches for advanced prostate cancer - such as androgen deprivation, chemotherapy, radiation - come up often against lack of effectiveness because of possible arising of correlative cancer cell resistance and/or inadequate anti-tumor immune conditions.
Whence the timeliness of resorting to immune-based treatment strategies including either therapeutic vaccination-based active immunotherapy or anti-tumor monoclonal antibody-mediated passive immunotherapy.
Particularly attractive, as for research studies and clinical applications, results to be the cytotoxic T-lymphocyte check point blockade by the use of anti-CTLA-4 and PD-1 monoclonal antibodies, particularly when combined with androgen deprivation therapy or radiation. Unlike afore said immune check point inhibitors, both cell-based (by the use of prostate specific antigen carriers autologous dendritic cells or even whole cancer cells) and recombinant viral vector vaccines are able to induce immune-mediated focused killing of specific antigen-presenting prostate cancer cells. Such vaccines, either used alone or concurrently/sequentially combined with above-mentioned conventional therapies, led to generally reach, in the field of various clinical trials, reasonable results particularly as regards the patient's overall survival. Adoptive trasferred T-cells, as adoptive T-cell passive immunotherapy, and monoclonal antibodies against specific antigen-endowed prostate cancer cells can improve immune micro-environmental conditions. On the basis of a preliminary survey about various immunotherapy strategies, are here also outlined their effects when combined with androgen deprivation therapy or radiation. What's more, as regard the immune-based treatment effectiveness, it has to be pointed out that suitable personalized epigenetic/gene profile-achieved pharmacogenomic approaches to target identified gene aberrations, may lead to overcome – as well as for conventional therapies – possible prostate cancer resistance to immunotherapy.

Vol. XXXVII (No. 6) 2016 November-December

  1. Mannheim Peritonitis Index (MPI) and elderly population: prognostic evaluation in acute secondary peritonitis
    Salamone G., Licari L., Falco N., Augello G., Tutino R., Campanella S., Guercio G., Gulotta G.
    doi: 10.11138/gchir/2016.37.6.243
  2. Early discharge after total thyroidectomy: a retrospective feasibility study
    Tartaglia F., Giuliani A., Sorrenti S., Tromba L., Carbotta S., Maturo A., Carbotta G., De Anna L., Merola R., Livadoti G., Pelle F., Ulisse S.
    doi: 10.11138/gchir/2016.37.6.250
  3. Open sphincter-preserving surgery of extraperitoneal rectal cancer without primary stoma and Fast Track Protocol
    Pappalardo G., Coiro S., De Lucia F., Giannella A., Ruffolo F., Frattaroli F.M.
    doi: 10.11138/gchir/2016.37.6.257
  4. Is it really useful the Harmonic scalpel in axillary dissection for locally advanced breast cancer? A case series
    Militello G., De Marco P., Falco N., Kabhuli K., Mascolino A., Licari L., Tutino R., Cocorullo G., Gulotta G.
    doi: 10.11138/gchir/2016.37.6.262
  5. Topical hemostasis in laparoscopic surgery
    Vecchio R., Catalano R., Basile F., Spataro C., Caputo M., Intagliata E.
    doi: 10.11138/gchir/2016.37.6.266
  6. Long lasting postoperative ileus after surgery for intestinal obstruction due to left paraduodenal hernia (LPDH). Case report
    Volpi A., Ialongo P., Panebianco A., Lozito R., Prestera A., Laforgia R., Punzo C., Palasciano N.
    doi: 10.11138/gchir/2016.37.6.271
  7. Neuroendocrine tumor of the common bile duct: case report
    Raspanti C., Falco N., Silvestri V., Rotolo G., Bonventre S., Gulotta G.
    doi: 10.11138/gchir/2016.37.6.275
  8. Small bowel obstruction caused by Anisakis and Meckel’s diverticulum: a rare case
    Carbotta G., Laforgia R., Milella M., Sederino M.G., Minafra M., Fortarezza F., Piscitelli D., Palasciano N.
    doi: 10.11138/gchir/2016.37.6.281
  9. XIX CONGRESSO MULTIDISCIPLINARE - Ricerca Scientifica ed Innovazione Tecnologica Etica e Sostenibilità
    Di Matteo G.
  10. 27° CONGRESSO CHIRURGIA DELL’APPARATO DIGERENTE
    Di Matteo G.
  11. Prof. Antonio Petrassi
    Di Matteo G.
Last Viewed articles: la lista degli ultimi x visitati.
  1. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
    Alberti C.
    doi: 10.11138/gchir/2016.37.5.225
credits